Inactive Instrument

Senzime AB (publ) Stock Nasdaq Stockholm

Equities

SE0002478776

Medical Equipment, Supplies & Distribution

Financials

Sales 2024 * 74M 7.05M 9.61M Sales 2025 * 180M 17.15M 23.37M Capitalization 904M 86.12M 117M
Net income 2024 * -103M -9.81M -13.37M Net income 2025 * -40M -3.81M -5.19M EV / Sales 2024 * 11.7 x
Net cash position 2024 * 36M 3.43M 4.67M Net cash position 2025 * - 0 0 EV / Sales 2025 * 5.02 x
P/E ratio 2024 *
-8.78 x
P/E ratio 2025 *
-22.9 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 53.5%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 51 15-12-31
Director of Finance/CFO 54 21-12-31
Chief Tech/Sci/R&D Officer 48 19-12-31
Members of the board TitleAgeSince
Chief Executive Officer 51 15-12-31
Director/Board Member 72 22-12-31
Director/Board Member 51 99-12-31
More insiders
Senzime publ AB is a Sweden-based company engaged in the development, manufacture and marketing of biosensors for measuring metabolites in biological fluids, such as human blood and cell culture substrates for the pharmaceutical and healthcare segments. The Company focuses on the following application areas: medical diagnostic instruments, pharmaceutical industry, chemical processing, and food and beverage processing. As of December 31, 2011, the Company marketed three products, namely SENZ-100G, for continuous analysis of glucose in the fermentation solutions; SENZ-100L, for continuous analysis of lactate in fermentation solutions, and SENZ-200G, for continuous analysis of glucose in blood during intensive care.
Calendar
More about the company